Clinical outcomes of hyperprogression based on volumetry in non‐small cell lung cancer after immune checkpoint inhibitor treatment
Abstract Background Hyperprogressive disease (HPD) is a novel pattern of the treatment course after immune checkpoint inhibitor (ICI) therapy in patients with non‐small cell lung cancer (NSCLC). This study aimed to investigate the clinical characteristics, outcomes, and associated factors of HPD usi...
| Main Authors: | , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2022-08-01
|
| Series: | Thoracic Cancer |
| Subjects: | |
| Online Access: | https://doi.org/10.1111/1759-7714.14539 |
| _version_ | 1818537401242353664 |
|---|---|
| author | Jehun Kim Taeyun Kim Tae Won Jang Hee Kang Mi Hyun Kim Seong Hoon Yoon Choon‐Hee Son Hyun‐Kyung Lee Hyun‐Kuk Kim Shin Yup Lee Kyeong Choel Shin Ji‐Yeon Han Eun‐Ju Kang |
| author_facet | Jehun Kim Taeyun Kim Tae Won Jang Hee Kang Mi Hyun Kim Seong Hoon Yoon Choon‐Hee Son Hyun‐Kyung Lee Hyun‐Kuk Kim Shin Yup Lee Kyeong Choel Shin Ji‐Yeon Han Eun‐Ju Kang |
| author_sort | Jehun Kim |
| collection | DOAJ |
| description | Abstract Background Hyperprogressive disease (HPD) is a novel pattern of the treatment course after immune checkpoint inhibitor (ICI) therapy in patients with non‐small cell lung cancer (NSCLC). This study aimed to investigate the clinical characteristics, outcomes, and associated factors of HPD using a semiautomatic volume measurement. Methods This retrospective study enrolled patients with recurrent and/or metastatic NSCLC treated with ICIs between January 2015 and August 2019 at eight tertiary centers in Korea. HPD was defined according to the tumor growth kinetics and time to treatment failure. Tumor volume was measured using a semiautomatic software. Results A total of 219 NSCLC patients with 35 HPD by volumetric measurement (HPDv) (15.9%) were enrolled. The median duration of overall survival (OS) and OS after ICI treatment (ICI‐OS) were 34.5 and 18.4 months, respectively. HPDv patients had significantly worse progression‐free survival (PFS) than progressive disease patients without HPDv (1.16 vs. 1.82 months, p‐value <0.001). ICI‐OS did not significantly differ between patients with HPDv and those without HPDv (2.66 vs. 5.4 months, p = 0.105). PD‐L1 expression lower than 50%, more than three metastatic sites, neutrophil‐to‐lymphocyte ratio equal to or higher than 3.3, and hemoglobin level lower than 10 were found to be associated with HPDv. Conclusions There is no standardized definition of HPD. However, defining HPD in NSCLC patients treated with ICI using a semiautomatic volume measurement software is feasible. |
| first_indexed | 2024-12-11T18:50:19Z |
| format | Article |
| id | doaj.art-517e3bdb2df344c2b1eb5ef134c75b9a |
| institution | Directory Open Access Journal |
| issn | 1759-7706 1759-7714 |
| language | English |
| last_indexed | 2024-12-11T18:50:19Z |
| publishDate | 2022-08-01 |
| publisher | Wiley |
| record_format | Article |
| series | Thoracic Cancer |
| spelling | doaj.art-517e3bdb2df344c2b1eb5ef134c75b9a2022-12-22T00:54:19ZengWileyThoracic Cancer1759-77061759-77142022-08-0113152170217910.1111/1759-7714.14539Clinical outcomes of hyperprogression based on volumetry in non‐small cell lung cancer after immune checkpoint inhibitor treatmentJehun Kim0Taeyun Kim1Tae Won Jang2Hee Kang3Mi Hyun Kim4Seong Hoon Yoon5Choon‐Hee Son6Hyun‐Kyung Lee7Hyun‐Kuk Kim8Shin Yup Lee9Kyeong Choel Shin10Ji‐Yeon Han11Eun‐Ju Kang12Division of Pulmonology, Department of Internal Medicine Kosin University College of Medicine, Kosin University Gospel Hospital Busan South KoreaDepartment of Internal Medicine The Armed Forces Goyang Hospital Goyang‐si South KoreaDivision of Pulmonology, Department of Internal Medicine Kosin University College of Medicine, Kosin University Gospel Hospital Busan South KoreaDepartment of Radiology Kosin University College of Medicine, Kosin University Gospel Hospital Busan South KoreaDivision of Pulmonology, Department of Internal Medicine Pusan National University Hospital Pusan South KoreaDivision of Pulmonology, Department of Internal Medicine Pusan National University Yangsan Hospital Yangsan South KoreaDivision of Pulmonology, Department of Internal Medicine Gwanghye General Hospital Pusan South KoreaDivision of Pulmonology, Department of Internal Medicine Inje University Busan Paik Hospital Busan South KoreaDivision of Pulmonology, Department of Internal Medicine Inje University Haeundae Paik Hospital Busan South KoreaDivision of Pulmonology, Department of Internal Medicine Kyungpook National University Chilgok Hospital Daegu South KoreaDivision of Pulmonology, Department of Internal Medicine Yeungnam University Hospital Daegu South KoreaDepartment of Radiology Inje University Busan Paik Hospital Busan South KoreaDepartment of Radiology Dong‐A University College of Medicine Busan South KoreaAbstract Background Hyperprogressive disease (HPD) is a novel pattern of the treatment course after immune checkpoint inhibitor (ICI) therapy in patients with non‐small cell lung cancer (NSCLC). This study aimed to investigate the clinical characteristics, outcomes, and associated factors of HPD using a semiautomatic volume measurement. Methods This retrospective study enrolled patients with recurrent and/or metastatic NSCLC treated with ICIs between January 2015 and August 2019 at eight tertiary centers in Korea. HPD was defined according to the tumor growth kinetics and time to treatment failure. Tumor volume was measured using a semiautomatic software. Results A total of 219 NSCLC patients with 35 HPD by volumetric measurement (HPDv) (15.9%) were enrolled. The median duration of overall survival (OS) and OS after ICI treatment (ICI‐OS) were 34.5 and 18.4 months, respectively. HPDv patients had significantly worse progression‐free survival (PFS) than progressive disease patients without HPDv (1.16 vs. 1.82 months, p‐value <0.001). ICI‐OS did not significantly differ between patients with HPDv and those without HPDv (2.66 vs. 5.4 months, p = 0.105). PD‐L1 expression lower than 50%, more than three metastatic sites, neutrophil‐to‐lymphocyte ratio equal to or higher than 3.3, and hemoglobin level lower than 10 were found to be associated with HPDv. Conclusions There is no standardized definition of HPD. However, defining HPD in NSCLC patients treated with ICI using a semiautomatic volume measurement software is feasible.https://doi.org/10.1111/1759-7714.14539hyperprogressionimmune checkpoint inhibitornon‐small cell lung cancervolumetry |
| spellingShingle | Jehun Kim Taeyun Kim Tae Won Jang Hee Kang Mi Hyun Kim Seong Hoon Yoon Choon‐Hee Son Hyun‐Kyung Lee Hyun‐Kuk Kim Shin Yup Lee Kyeong Choel Shin Ji‐Yeon Han Eun‐Ju Kang Clinical outcomes of hyperprogression based on volumetry in non‐small cell lung cancer after immune checkpoint inhibitor treatment Thoracic Cancer hyperprogression immune checkpoint inhibitor non‐small cell lung cancer volumetry |
| title | Clinical outcomes of hyperprogression based on volumetry in non‐small cell lung cancer after immune checkpoint inhibitor treatment |
| title_full | Clinical outcomes of hyperprogression based on volumetry in non‐small cell lung cancer after immune checkpoint inhibitor treatment |
| title_fullStr | Clinical outcomes of hyperprogression based on volumetry in non‐small cell lung cancer after immune checkpoint inhibitor treatment |
| title_full_unstemmed | Clinical outcomes of hyperprogression based on volumetry in non‐small cell lung cancer after immune checkpoint inhibitor treatment |
| title_short | Clinical outcomes of hyperprogression based on volumetry in non‐small cell lung cancer after immune checkpoint inhibitor treatment |
| title_sort | clinical outcomes of hyperprogression based on volumetry in non small cell lung cancer after immune checkpoint inhibitor treatment |
| topic | hyperprogression immune checkpoint inhibitor non‐small cell lung cancer volumetry |
| url | https://doi.org/10.1111/1759-7714.14539 |
| work_keys_str_mv | AT jehunkim clinicaloutcomesofhyperprogressionbasedonvolumetryinnonsmallcelllungcancerafterimmunecheckpointinhibitortreatment AT taeyunkim clinicaloutcomesofhyperprogressionbasedonvolumetryinnonsmallcelllungcancerafterimmunecheckpointinhibitortreatment AT taewonjang clinicaloutcomesofhyperprogressionbasedonvolumetryinnonsmallcelllungcancerafterimmunecheckpointinhibitortreatment AT heekang clinicaloutcomesofhyperprogressionbasedonvolumetryinnonsmallcelllungcancerafterimmunecheckpointinhibitortreatment AT mihyunkim clinicaloutcomesofhyperprogressionbasedonvolumetryinnonsmallcelllungcancerafterimmunecheckpointinhibitortreatment AT seonghoonyoon clinicaloutcomesofhyperprogressionbasedonvolumetryinnonsmallcelllungcancerafterimmunecheckpointinhibitortreatment AT choonheeson clinicaloutcomesofhyperprogressionbasedonvolumetryinnonsmallcelllungcancerafterimmunecheckpointinhibitortreatment AT hyunkyunglee clinicaloutcomesofhyperprogressionbasedonvolumetryinnonsmallcelllungcancerafterimmunecheckpointinhibitortreatment AT hyunkukkim clinicaloutcomesofhyperprogressionbasedonvolumetryinnonsmallcelllungcancerafterimmunecheckpointinhibitortreatment AT shinyuplee clinicaloutcomesofhyperprogressionbasedonvolumetryinnonsmallcelllungcancerafterimmunecheckpointinhibitortreatment AT kyeongchoelshin clinicaloutcomesofhyperprogressionbasedonvolumetryinnonsmallcelllungcancerafterimmunecheckpointinhibitortreatment AT jiyeonhan clinicaloutcomesofhyperprogressionbasedonvolumetryinnonsmallcelllungcancerafterimmunecheckpointinhibitortreatment AT eunjukang clinicaloutcomesofhyperprogressionbasedonvolumetryinnonsmallcelllungcancerafterimmunecheckpointinhibitortreatment |